D2 receptor occupancy under recommended and high doses of olanzapine: An iodine-123-iodobenzamide SPECT study

Journal of Psychopharmacology

Volumn 14, Issue 4, 2000, Pages 364-370

  Meisenzahl, E M ^a   Dresel, S ^a   Frodl, T ^a   Schmitt, G J E ^a   Preuss, U W ^a   Rossmuller B ^a   Tatsch, K ^a   Mager, T ^a   Hahn, K ^a   Moller H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atypical neuroleptics; Olanzapine; SPECT

Indexed keywords

BIPERIDEN; DOPAMINE 2 RECEPTOR; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PIRENZEPINE; PYRROLIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; DOSE RESPONSE; DRUG RECEPTOR BINDING; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MONOTHERAPY; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOIDISM; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; BRAIN LEVEL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; METABOLISM; MIDDLE AGED; PSYCHOSIS; SCINTISCANNING;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZAMIDES; BENZODIAZEPINES; BRAIN; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHOTIC DISORDERS; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034353113     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110001400405     Document Type: Article

References (40)

1. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics
2. Stiatal dopamine receptor occupancy following withdrawl from neuroleptic treatment: Correlative evaluation by positron emission tomography and plasma prolactin levels
3. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
4. 2dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects
5. 2-receptor blockade by typical and atypical neuroleptics
6. Radioreceptor binding profile of the atypical antipsychotic olanzapine
7. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
8. 2 receptor occupancy in risperidone-treated schizophrenic patients
9. In vivo effects of olanzapine on striatal dopamine D2/D3 receptor binding in schizophrenic patients: An iodine-123-iodobenzamide single-photon emission tomography study
10. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine
11. 2 receptors: Distribution, pharmacological characterisation and region specific regulation by clozapine
12. Treatment of schizophrenia
13. Schizophrenia
14. 2 receptor occupancy and plama levels on low dose oral haloperidol: A PET study
15. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
16. 2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia
17. 2 receptors with typical and atypical antipsychotics
18. 2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics
19. 2-dopaminergic receptors in the primate cerebral cortex
20. The concept of atypical antipsychotics
21. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients
22. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients
23. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients
24. 2 receptor occupancy studies and clinical response
25. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects
26. 2 dopamine receptor blockade hypothesis of schizophrenia
27. 2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 1231-IBZM single photon emission computerised tomography study
28. 123I IBZM single photon emission tomography (SPECT) study
29. 2 and 5-HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET
30. 2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects
31. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics
32. High-dose olanzapine for treatment-refractory schizophrenia
33. Deriving the therapeutic concentrations for clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the D2 or D4 receptor varies with the affinity of the competing radioligand
34. Antipsychotic drugs which elict little or no parkinsonism bind more looseley than dopamine to brain D2 receptors, yet occupy high levels of these receptors
35. 123I IBZM SPECT to differentiate idiopathic parkinson syndroms
36. Previous treatment as a confounding variable in studies with novel antipsychotics: Two cases of high dopamine-2 receptor occupancy with quetiapine
37. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol
38. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
39. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
40. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia